Scarica l'app Stockscreener
126.75
0.98%
-1.25
Dopo l'orario di chiusura:
126.75
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Incyte Corp Borsa (INCY) Ultime notizie
Incyte Corp. (INCY) Peer Comparison – Compare with Others - valueresearchonline.com
Incyte Corp. (INCY) Financials – Balance Sheet, Profit & Loss, Cash Flow - valueresearchonline.com
Incyte (INCY) Institutional Ownership 2026 $INCY - MarketBeat
Incyte Corp. (INCY) Key Financial Ratios – Valuation, Profitability & More - valueresearchonline.com
Incyte Corp. stock underperforms Wednesday when compared to competitors despite daily gains - MarketWatch
Incyte Corp. stock underperforms Tuesday when compared to competitors despite daily gains - MarketWatch
H.C. Wainwright reiterates Incyte stock rating on Medicaid pricing deal - Investing.com
Incyte to Present at Upcoming Investor Conferences - Yahoo Finance
BMO reiterates Incyte stock rating on CMS pricing agreement - Investing.com
Incyte (INCY) Enters Agreement With CMS to Improve Medicaid Acce - GuruFocus
Incyte agrees CMS pricing deal for Jakafi, avoids certain future mandates; no change to 2026 guidance - TradingView
Incyte (NASDAQ: INCY) expects to sidestep new CMS drug pricing rules - Stock Titan
Incyte Corporation Enters Agreement with U.S. Centers for Medicare & Medicaid Services - marketscreener.com
Josh Brown Says ‘Take a Break From AI CapEx World,’ Highlights His 2 Top Healthcare Stock Picks - Yahoo Finance
Incyte Corp. stock underperforms Friday when compared to competitors - MarketWatch
Incyte stock price target maintained at $150 by H.C. Wainwright - Investing.com
Incyte (NASDAQ: INCY) HR chief holds 10,993 shares after tax withholding - Stock Titan
Incyte Corp. stock underperforms Wednesday when compared to competitors - MarketWatch
Incyte president Pablo Cagnoni sells $1.36m of INCY shares By Investing.com - Investing.com Nigeria
symbol__ Stock Quote Price and Forecast - CNN
Here’s How Much You Would Have Made Owning Incyte Stock In The Last 20 Years - Benzinga
Insider Selling: Incyte (NASDAQ:INCY) Insider Sells $1,356,173.56 in Stock - MarketBeat
Incyte Corp's R&D Head Pablo J. Cagnoni Sells 10,801 Shares via 10b5-1 Trading Plan - Kalkine Media
Incyte (INCY) R&D head sells 10,801 shares, holds 183,200 in awards - Stock Titan
INCY Initiates Coverage On Canaccord Genuity -- Rating Set to Bu - GuruFocus
Incyte (INCY) Quarter in Focus: The EPS Result Is Above Expectation for the Current Session; Stock Move: The Market Price Advances 4.05% on the DayRevenue Guidance Update - vinanet.vn
INCY Reiterated by HC Wainwright & Co. -- Price Target Maintained at $150 - GuruFocus
H.C. Wainwright reiterates Incyte stock rating on cancer trial data - Investing.com
Incyte (NASDAQ:INCY) Receives Buy Rating from HC Wainwright - MarketBeat
Incyte (NASDAQ:INCY) Earns Buy Rating from Analysts at Canaccord Genuity Group - MarketBeat
H.C. Wainwright reiterates Incyte stock rating on cancer trial data By Investing.com - Investing.com UK
Canaccord Genuity Initiates Incyte at Buy With $152 Price Target - marketscreener.com
DCF Advisers LLC Takes Position in Incyte Corporation $INCY - MarketBeat
BlackRock Inc. Takes $2.04 Billion Position in Incyte Corporation $INCY - MarketBeat
Incyte Corporation: Target Price Consensus and Analysts Recommendations | ICY | US45337C1027 - marketscreener.com
US FDA approves Regeneron's rare bone disorder drug - marketscreener.com
INCY Looks 19.9% Overvalued on GF Value™ as Insider Selling Pers - GuruFocus
Incyte (INCY) Financial Update: Profit Per Share Surpasses Its Benchmark in the Latest Reading - Vinanet
State of Wyoming's Incyte Corp(INCY) Holding History - GuruFocus
Incyte Stock: Is Wall Street Bullish or Bearish? - Yahoo Finance
Incyte Corp. stock outperforms competitors on strong trading day - MarketWatch
INCY Maintained by Piper Sandler -- Price Target Raised to $130 - GuruFocus
Global Vitiligo Foundation Applauds Incyte’s "Moments of Clarity" Campaign for Elevating Patient Voices and Advancing Vitiligo Awareness - Yahoo Finance
Incyte stock holds at the $120 mark as strong quarterly earnings support valuation - AD HOC NEWS
Incyte (NASDAQ:INCY) Combines High Growth Momentum with a Breakout Setup - ChartMill
State of Wyoming Acquires New Holdings in Incyte Corporation $INCY - MarketBeat
LTS:0J9P EV-to-OCF: 10.03 — 48% Below Median - GuruFocus
55,370 Shares in Incyte Corporation $INCY Bought by Summit Global Investments - MarketBeat
Baird Chautauqua Global Growth Fund's Incyte Corp(INCY) Holding History - GuruFocus
Incyte Corp's Pablo J. Cagnoni Sells 10,803 Shares Under Rule 10b5-1 Plan in August 2026 - Kalkine Media
Incyte Corp (INCY) R&D chief sells 10,803 shares under Rule 10b5-1 plan - Stock Titan
Incyte Corporation (INCY) Stock Price, News, Quote & History - Yahoo! Finance Canada
Incyte Corporation (INCY) has the Bigger Revenue Base, but Could Halozyme Therapeutics, Inc. (HALO) have the Better Economics? - Yahoo Finance
Incyte stock gains support as Q2 2026 sales surge and guidance rises - AD HOC NEWS
Bernstein Adjusts Price Target on Incyte to $104 From $99, Keeps Market Perform Rating - marketscreener.com
Incyte Sales Growth Drives Share Price Gains - FXEmpire
Insight Wealth Strategies LLC Acquires New Position in Incyte Corporation $INCY - MarketBeat
Q4 2025 Incyte Corp Earnings Call Transcript - GuruFocus
0.86%
0.31%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):